Translation

Trial Use of Electric Vehicles
- Enhancement of Preventive Measures Against Global Warming -

September 9, 2010 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced today that Chugai has started the trial use of electric vehicles (i-MiEV made by Mitsubishi Motors) at its Kamakura Site on September 8, 2010 to enhance its efforts for the prevention of global warming.

Chugai has set a goal of making 50 percent of the vehicles used by its medical representatives hybrid vehicles by 2012, as one of the preventive measures against global warming. Since 2003, Chugai is among the first in the pharmaceutical industry to introduce hybrid vehicles. As a result, the number of hybrid vehicles currently used reached 522 as of July 31, 2010, accounting for about 30 percent of the leased vehicles that are used by the medical representatives.

To further enhance the measures against global warming, Chugai will determine the possibility of fully introducing the electric vehicles after investigating practical aspects such as convenience and cost-effectiveness. The trial use of electric vehicles is also planned at Fuji-Gotemba Research Laboratories and Fujieda Plant of Chugai Pharma Manufacturing Co., Ltd., a wholly-owned subsidiary of Chugai. The use of the three electric vehicles is expected to reduce the emission of carbon dioxide by eight tons annually.

With an aim of becoming a top Japanese pharmaceutical company, Chugai will not only supply innovative pharmaceutical products and services, but also be involved in social contribution activities to protect the global environment.